Pfizer Stalls Generic Lipitor With Ranbaxy Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Settlement could give 20 more months of unchallenged U.S. marketing.
You may also be interested in...
As Launch Date Nears, Is Ranbaxy Exploring Talks To Monetize Lipitor First-launch Opportunity With Generic Rivals?
Agreement with Impax on launch of generic tamsulosin could be one model for atorvastatin strategy.
As Launch Date Nears, Is Ranbaxy Exploring Talks To Monetize Lipitor First-launch Opportunity With Generic Rivals?
Agreement with Impax on launch of generic tamsulosin could be one model for atorvastatin strategy.
As Launch Date Nears, Is Ranbaxy Exploring Talks To Monetize Lipitor First-launch Opportunity With Generic Rivals?
MUMBAI - As Ranbaxy struggles to deal with U.S. FDA allegations of GMP violations and data falsification at its two Indian manufacturing sites - Paonta Sahib and Dewas - clouds are gathering over its ability to launch a generic equivalent of the planet's largest drug brand Lipitor (atorvastatin) in the United States, about a year from now